aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company (“aVenture”) is an independent research platform providing information and analysis about startups.
Certain metrics provided by aVenture may seek to assess the risks and opportunities associated with a company, fund, or its representatives (collectively “research”). aVenture seeks to provide this information with objectivity and fairness, and with diligence about its accuracy. Nonetheless, aVenture cannot provide assurance as to the accuracy of the information provided by our research. We strongly advise those using the research platform to seek multiple, independent sources for your research when making financial decisions.
Any links provided to other websites are offered as a matter of convenience and are not intended to imply that aVenture or its authors endorse, sponsor, promote, and/or are affiliated with the owners of or participants in those sites.
The aVenture platform also provides investment listings offered by independent investment advisers in the United States. aVenture is neither a registered investment adviser nor an exempt reporting adviser under the Investment Advisers Act of 1940, and no statements made by aVenture are intended to imply any financial instruments are under the counsel or advice of aVenture or its representatives.
Funds offered on the platform are generally managed by a private investment adviser that, unless stated otherwise, claims exemption from SEC or state registration. Investment funds presented on the platform are only available to investors who meet the requirements of the offering, and solicitations are not made outside those listed jurisdictions.
Additionally, each investment offered on the platform has qualifications for eligibility, including some offered only to Qualified Clients and/or Accredited Investors. Certain funds may be available to non-Qualified or Accredited investors, but only those who become personally known and identifiable to aVenture Investment Company staff, who have had an opportunity to assess the financial capacity and suitability for such an investment, and discuss its risks. Funds, when offered, are only offered following a review of a Private Placement Memorandum (PPM), subscription agreement, and other disclosures.
Investments in startups, venture capital, angel investments, private equity, real estate, stocks, and similar asset classes all involve risks, including: the risk of a decline in the value of your investments, including potentially large declines (suddenly and/or for long periods of time), the potential for illiquidity where part or all of a withdrawal request may not be honored on the date requested (even when a feature of the fund). These risks are heightened during periods of market duress.
Diversification has the possibility of reducing the magnitude of declines (either caused by market/economic factors, or by factors related to the individual company), but does not guarantee these risks have been fully or partially alleviated. Most importantly, past results are not an assurance of future outcomes. While most of these risks are shared and similarly held by other investment asset classes, we recommend investors only consider venture capital investments as part of a broader, diversified portfolio of stocks, bonds, and immediately accessible cash reserves.
From Startups | TechCrunch
By Marina Temkin
April 16, 2024
When Alex Katz founded Two Chairs in 2017, he firmly believed that in-person therapy is the most effective for behavioral health.
Two Chairs used technology — a proprietary matching algorithm — to find the best possible therapists for its clients, but treatments took place primarily inside one of the startup’s half a dozen stylishly designed clinics located in prime locations throughout the San Francisco Bay Area.
But when COVID-19 erupted and the whole world moved online, the company was forced to reconsider its face-to-face approach. While Two Chairs now operates at least one brick-and-mortar site in each of the three states it serves — California, Washington and Florida — the majority of the company’s more than 500 therapists treat clients virtually.
The adoption of the remote-first treatment model has likely helped the company to grow faster (and certainly less expensively) than it would have had it continued to emphasize seeing patients in person. Two Chairs says its revenue expanded eightfold over the last three years.
On Tuesday, the company announced a $72 million Series C equity and debt financing round led by Amplo and Fifth Down Capital, bringing Two Chairs’ total funding to $103 million. Amplo also led the company’s $22.5 million Series B in August 2019. The debt portion, which comprised the minority of the latest capital, was provided by Bridge Bank.
Two Chairs is one of the latest therapy startups to raise substantial funding rounds. Last week, Grow Therapy, a three-sided mental health platform for therapists, payers and patients, raised an $88 million Series C round led by Sequoia.
Katz says that the primary difference between his company and other virtual behavioral health platforms, including Talkspace and Teladoc-owned BetterHelp, is that Two Chairs employs the “vast majority” of its therapists while most competitors contract with their clinicians. “That enables us to select therapists that we think are really high quality, and then we can train them on how to use measurement-based care,” he explained. Clinicians who use measurement-based care (MBC) could improve outcomes and reduce costs by assessing patients’ progress against standard metrics, but only a small portion of therapists use MBC in their practice, according to Katz.
Availability of remote therapy from independent clinicians, established institutions and startups like Two Chairs has been helping solve the shortage of mental health professionals in the U.S., but Katz says that online psychotherapy is not the panacea.
“While it has gotten easier to find a therapist because of different digital platforms, it’s still just as hard to find the right therapists and really high-quality care, and that’s the problem we’re trying to solve,” he said. “We still have far more demand than we can serve.”
Two Chairs will use its new capital to hire more therapists, expand into new states and improve its technology. The company currently offers its services for the price of a co-pay to Aetna and Kaiser Permanente health insurance holders and charges $226 a session for other individuals.
As for whether AI could one day replace mental health professionals, and therefore make a business like Two Chairs even more effective, Katz wasn’t so sure it’s going to happen anytime soon. “It is such a human, emotionally driven job, and that’s only possible [to do well] with a great therapist in the room,” he said.
View original article on techcrunch.com
Share:
Xaira, an AI drug discovery startup, launches with a massive $1B, says it’s ‘ready’ to start developing drugs
Advances in generative AI have taken the tech world by storm. Biotech investors are making a big bet that similar computational methods could revolutionize drug discovery. On Tuesday, ARCH Venture Partners and Foresite Labs, an affiliate of Foresite Capital, announced that they incubated Xaira Therapeutics and funded the AI biotech with $1 billion. Other investors […] © 2024 TechCrunch. All rights reserved. For personal use only.
Apr 25, 2024
Eric Schmidt-backed Augment, a GitHub Copilot rival, launches out of stealth with $252M
AI is supercharging coding — and developers are embracing it. In a recent StackOverflow poll, 44% of software engineers said that they use AI tools as part of their development processes now and 26% plan to soon. Gartner estimates that over half of organizations are currently piloting or have already deployed AI-driven coding assistants, and […] © 2024 TechCrunch. All rights reserved. For personal use only.
Apr 24, 2024
Radical thinks the time has come for solar-powered, high-altitude autonomous aircraft
Though many eyes are on space as orbit develops into a thriving business ecosystem, Radical is keeping things a little closer to the ground — but not too close. Its high-altitude, solar-powered aircraft aim to succeed where Facebook’s infamous Aquila failed by refining the tech and embracing more markets. It’s hard to believe that Facebook’s […] © 2024 TechCrunch. All rights reserved. For personal use only.
Apr 24, 2024
Don't miss our latest news and updates. Subscribe to the newsletter
More from Tech Crunch: